Literature DB >> 1851154

5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives.

J Balzarini1, E De Clercq.   

Abstract

The acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) are potent inhibitors of DNA viruses and retroviruses, respectively. Unlike nucleoside triphosphates, the metabolically active (diphosphorylated) forms of HPMPA and PMEA (designated HPMPApp and PMEApp) are synthesized in a reversible reaction in which the pyrophosphate group of 5-phosphoribosyl 1-pyrophosphate (PRPP) is directly transferred to HPMPA and PMEA by purified PRPP synthetase. In this respect, PRPP synthetase does not act stereospecifically in that it recognizes both the S-enantiomer and the R-enantiomer of HPMPA as substrate. PRPP synthetase also recognizes other acyclic adenine and 2,6-diaminopurine riboside phosphonates as a substrate. It is now imperative to evaluate the potential role of PRPP synthetase, as activating enzyme, in the antiviral action of this type of molecules in intact cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851154

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.

Authors:  K C Cundy
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

2.  Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.

Authors:  J Neyts; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

3.  Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds.

Authors:  G Andrei; R Snoeck; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

4.  Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.

Authors:  L Naesens; J Balzarini; N Bischofberger; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice.

Authors:  J Balzarini; T Vahlenkamp; H Egberink; K Hartmann; M Witvrouw; C Pannecouque; P Casara; J F Navé; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

Review 6.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

7.  The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity.

Authors:  M A Becker; P R Smith; W Taylor; R Mustafi; R L Switzer
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

8.  Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.

Authors:  Bruno Marchand; Kirsten L White; John K Ly; Nicolas A Margot; Ruth Wang; Martin McDermott; Michael D Miller; Matthias Götte
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 9.  Acyclic nucleosides as antiviral compounds.

Authors:  S Freeman; J M Gardiner
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

10.  Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.

Authors:  A S Mulato; P D Lamy; M D Miller; W X Li; K E Anton; N S Hellmann; J M Cherrington
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.